Literature DB >> 7493294

Hepatitis C virus infection in the asymptomatic British blood donor.

D J Mutimer1, R F Harrison, K B O'Donnell, J Shaw, B A Martin, H Atrah, F A Ala, S Skidmore, S G Hubscher, J M Neuberger.   

Abstract

Blood donor screening for hepatitis C virus (HCV) antibodies is now routine. Most blood transfusion services recommend that seropositive donors are referred for further investigation. Southern European studies suggest that many asymptomatic seropositive donors have clinically significant liver disease. Seropositive donors in areas of high prevalence may not, however, be representative of British donors. We have prospectively examined the prevalence and severity of HCV infection in a British volunteer blood donor population. During a 14 month period, only 0.35% (999/287,332) of all donors in the West Midlands were anti-HCV (screening assay) positive. Only 5% (52/999) of these were confirmed true seropositive. Nearly 80% (41/52) of seropositive donors were referred to the Queen Elizabeth Hospital Liver Unit for further investigation. Most underwent complete investigation, including liver biopsy. Forty of forty-one donors had biochemical, histological, or virological evidence of persistent viral infection. Histological changes were generally mild and none was cirrhotic. Covertly infected patients had less severe disease than those with an overt risk factor for HCV exposure. In the British Midlands, the prevalence of blood donor seropositivity is low. In contrast with seropositive Southern European donors, the British donor is more likely to belong to an at-risk group for parenteral exposure and is less likely to have severe histological changes. This study highlights the importance of developing locally relevant guidelines for the counselling and investigation of anti-HCV-positive blood donors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493294     DOI: 10.1111/j.1365-2893.1995.tb00071.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

2.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection.

Authors:  Vincent Lo Re; Kevin Haynes; Kimberly A Forde; A Russell Localio; Rita Schinnar; James D Lewis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-09       Impact factor: 2.890

4.  Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults.

Authors:  M E Cramp; H C Grundy; R M Perinpanayagam; D E Barnado
Journal:  J R Soc Med       Date:  1996-07       Impact factor: 5.344

5.  The management of chronic hepatitis C virus infection.

Authors:  J C Booth; J L Brown; H C Thomas
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

Review 6.  Sexual transmission of hepatitis C virus infection.

Authors:  G Rooney; R J Gilson
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

Review 7.  Pathophysiology and treatment of hepatitis C.

Authors:  H C Thomas; J Booth; J Brown
Journal:  Drugs       Date:  1996       Impact factor: 9.546

8.  Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy.

Authors:  C Skipper; J M Guy; J Parkes; P Roderick; W M Rosenberg
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

9.  Diagnostic Accuracy of Serum Hyaluronan for Detecting HCV Infection and Liver Fibrosis in Asymptomatic Blood Donors.

Authors:  Itatiana F Rodart; Madalena M Pares; Aline Mendes; Camila M Accardo; João R M Martins; Cleidenice B Silva; Fabrício O Carvalho; José A Barreto; Mitermayer G Reis; Ivarne L S Tersariol; Helena B Nader
Journal:  Molecules       Date:  2021-06-25       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.